PARP Inhibitors in Prostate Cancer: Practical Guidance for Busy Clinicians

  Abstract: The management of prostate cancer entered a new era of biomarker-driven therapy in May of 2020, when the US Food and Drug Administration (FDA) […]

PARP Inhibition as Frontline Therapy in Ovarian Cancer

  Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors have been rapidly integrated into clinical practice for women with ovarian cancer. Currently, PARP inhibitors are approved as frontline maintenance […]

Highlights in Prostate Cancer From the 2020 American Society of Clinical Oncology Annual Meeting

May 29-31, 2020 • Virtual   68Ga-PSMA-11 PET Has Poor Sensitivity, Good Specificity for Pelvic Nodal Metastases 68Ga-PSMA-11 positron emission tomography (PET) has poor sensitivity and […]

PARP Inhibitors in Breast Cancer

Abstract: The therapeutic implications of DNA damage in cancer therapy have long been appreciated and form the basis of many successful cytotoxic chemotherapy and radiotherapy treatment strategies. A novel class of DNA repair defect targeted therapeutics that inhibit poly (ADP-Ribose) polymerase (PARP) are being rapidly developed in breast cancer based on exciting preliminary clinical activity as single agents in BRCA mutation–associated breast cancer and in combination with chemotherapy in triple-negative breast cancer. Though there is widespread enthusiasm to move these drugs forward quickly, much remains to be understood about the optimal use of the novel agents. Here we review the clinical development of PARP inhibitors in breast cancer and highlight clinical trials in progress. We also provide commentary on a series of outstanding questions in the field, the answers to which will be critical for the successful development of PARP inhibitor–based strategies in early- and late-stage breast cancer.